Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVAMUNE vaccination for workers at risk of vaccinia exposure
2010-018334-51Phase 2Terminated
- Sponsor
- Bavarian Nordic
- Start
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of JYNNEOS in smallpox and vaccinia virus infection, sponsored by Bavarian Nordic. Primary endpoint: Vaccinia-specific immune response. Started Mar 2010; status: terminated.
02
Drugs
JYNNEOS
03
Conditions
smallpoxvaccinia virus infection
Beyond the preview
Go deeper on 2010-018334-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018334-51.